Analyze awards, watch incumbents and competitors, track new transactions or changes, and use award history to shape recompete and capture strategy.
Award ID | Description | Recipient | Total Value | Awarding Agency | Funding Agency | Set Aside | NAICS | PSC | Award Date | Start Date | End Date | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT. | OSIVAX | $743,969 | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | — | 541714Research and Development in Biotechnology (except Nanobiotechnology) | AN14HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES | Sep 19, 2025 | Sep 30, 2025 | Mar 31, 2027 | ||
| OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS | OSIVAX | $98,593,151 | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE | — | 541714Research and Development in Biotechnology (except Nanobiotechnology) | AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH | Jul 25, 2025 | Jul 25, 2025 | Jul 24, 2028 |